Zymeworks

November 04, 2019

SITC 2019 preview – Pieris joins the quest for a better Herceptin

Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.

September 10, 2019

Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus

Away from the main small-molecule focus of this year’s Esmo meeting, Keytruda flies the flag for immuno-oncology, including in a little-noticed mesothelioma study.

September 01, 2017

Macrogenics and J&J fallout could spell double trouble

July 05, 2017

Biotech floats come back with a vengeance

The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.

July 14, 2016

Biotech venture funding falls from 2015 peak

April 13, 2016

Zymeworks

SITC 2019 preview – Pieris joins the quest for a better Herceptin

Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus

Macrogenics and J&J fallout could spell double trouble

Biotech floats come back with a vengeance

Biotech venture funding falls from 2015 peak

First-quarter venture financing: the retrenchment begins

Latest Reports

Evaluate Vantage 2021 Preview

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Editor's Picks

What the coming year might hold for biopharma

Covid-19 vaccine developers remind the world that setbacks happen

Astrazeneca’s vaccine looks increasingly like an also-ran

Pfizer and Biontech snatch first Covid vaccine victory

The promise and the perils of antigen testing